GeoVax Labs Enters Material Definitive Agreement

TL;DR

GeoVax Labs signed a big deal on June 12th, 2024.

AI Summary

On June 12, 2024, GeoVax Labs, Inc. entered into a Material Definitive Agreement. The company, incorporated in Delaware with its principal office in Smyrna, GA, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates a significant new contract or partnership for GeoVax Labs, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks related to partnerships, financial obligations, or operational changes.

Key Numbers

• 001-39563 — SEC File Number (Identifies the company's filing with the SEC.)
• 87-0455038 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• GeoVax Labs, Inc. (company) — Registrant
• June 12, 2024 (date) — Date of earliest event reported
• Smyrna, GA (location) — Business Address City, State
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share GOVX The Nasdaq Capital Ma
• $24.3 m — direct award to GeoVax of approximately $24.3 million, which may increase to as much as
• $45 m — llion, which may increase to as much as $45 million, will fund the manufacturing of c
• $343M — at funding will represent approximately $343M from the Project NextGen program for a

Filing Documents

• govx20240618_8k.htm (8-K) — 29KB
• ex_689956.htm (EX-99.1) — 18KB
• logo01.jpg (GRAPHIC) — 5KB
• 0001437749-24-020615.txt ( ) — 213KB
• govx-20240612.xsd (EX-101.SCH) — 4KB
• govx-20240612_def.xml (EX-101.DEF) — 14KB
• govx-20240612_lab.xml (EX-101.LAB) — 18KB
• govx-20240612_pre.xml (EX-101.PRE) — 14KB
• govx20240618_8k_htm.xml (XML) — 5KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the "Filings") contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by the Company's management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to the Company or the Company's management identify forward looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company's industry, operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Company does not undertake to update its forward-looking statements.

01

Item 1.01 Entry into a Material Definitive Agreement On June 12, 2024, GeoVax, Inc. ("GeoVax" or the "Company") received an award (the "BARDA Contract") through the Rapid Response Partnership Vehicle (RRPV) to advance development of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, in a Phase 2b clinical trial. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). Under the agreement, the Company will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of GEO-CM04S1 with a U.S. Food and Drug Administration (FDA)-approved mRNA COVID-19 vaccine. Preparations for the study are underway, and execution of the study will be fully funded by BARDA under its Clinical Studies Network. The direct award to GeoVax of approximately $24.3 million, which may increase to as much as $45 million, will fund the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities. BARDA has made separate awards through its Clinical Studies Network to support execution of the study. That funding will represent approximately $343M from the Project NextGen program for a CRO to execute the clinical trial using GeoVax's vaccine. The foregoing description of the BARDA Contract does not purport to be complete and is qualified in its entirety by reference to the full text of the BARDA Contract, which will be filed as an exhibit to the Company's next periodic report on Form 10-Q. On June 18, 2024, the Company issued a press release announcing its entry into the BARDA Contract, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated June 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 18, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR